A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
Drug: Afimkibart
50 locations incl. Glendale
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819891·Phase 3·Recruiting